SS
LRMR icon

SBI Securities’s Larimar Therapeutics LRMR Stock Holding History

SBI Securities’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125 Sell
41
-997
-96% -$3.96K ﹤0.01% 3458
2026
Q1 		$4.67K Buy
1,038
+993
+2,207% +$3.97K ﹤0.01% 2055
2025
Q4 		$171 Sell
45
-37
-45% -$144 ﹤0.01% 3259
2025
Q3 		$265 Sell
82
-112
-58% -$420 ﹤0.01% 3224
2025
Q2 		$561 Buy
194
+3
+2% +$7 ﹤0.01% 2920
2025
Q1 		$411 Buy
191
+73
+62% +$231 ﹤0.01% 2941
2024
Q4 		$457 Buy
+118
New +$779 ﹤0.01% 2925

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

SBI Securities's LRMR Position: Q2 2026 in Review

SBI Securities reduced its Larimar Therapeutics (LRMR) stake by 96% in Q2 2026, selling an estimated $3.96K and leaving 41 shares worth $125. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

SBI Securities first reported a position in LRMR in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.67K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • SBI Securities held 41 shares of Larimar Therapeutics worth $125 as of Q2 2026.
  • SBI Securities sold 997 Larimar Therapeutics shares in Q2 2026, an estimated $3.96K.
  • Larimar Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3458 holding.
  • SBI Securities first reported a position in Larimar Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Larimar Therapeutics position peaked at $4.67K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.